Evidence map›Paper›PMID 42026126›Full record

ArticleNature microbiology2026

In silico typing maps the natural diversity of Escherichia coli transporter-dependent capsules.

Samuel Miravet-Verde, Elisabetta Cacace, Carine Roese Mores, Christoph Rutschmann, Chia-Wei Lin, Hans-Joachim Ruscheweyh, Aline Cuénod, Elisa Cappio Barazzone, Enora Marrec, Kateryna Vershynina and 8 more

Abstract read
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Samuel Miravet-Verde *Department of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland. smiravet@ethz.ch.ORCID http://orcid.org/0000-0002-1542-5912
Elisabetta Cacace *Department of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland. ecacace@ethz.ch.ORCID http://orcid.org/0000-0001-8239-0353
Carine Roese Mores *Department of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland.
Christoph RutschmannDepartment of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0004-0660-4283
Chia-Wei LinFunctional Genomics Centre Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4777-2916
Hans-Joachim RuscheweyhDepartment of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-7473-6086
Aline CuénodInstitute for Medical Microbiology, University of Zurich, Zurich, Switzerland.
Elisa Cappio BarazzoneDepartment of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-1295-4672
Enora MarrecDepartment of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland.
Kateryna VershyninaDepartment of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland.
Raffael SchumannDepartment of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-8401-4036
Dan J BowerQuadraticMed GmbH, Baar, Switzerland.ORCID http://orcid.org/0000-0002-0673-4860
Mario SchubertDepartment of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-0278-4091
Adrian EgliInstitute for Medical Microbiology, University of Zurich, Zurich, Switzerland.
Timm FiebigGerman Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.ORCID http://orcid.org/0000-0002-2021-7296
Emma SlackDepartment of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland. emma.slack@immune.engineering.ORCID http://orcid.org/0000-0002-2473-1145
Shinichi SunagawaDepartment of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland. ssunagawa@ethz.ch.ORCID http://orcid.org/0000-0003-3065-0314
Timothy G KeysDepartment of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland. timkeys@baxiva.com.ORCID http://orcid.org/0000-0003-2921-0362

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 865730Human Frontier Science Program (HFSP) LT0050/2023-LNovartis Stiftung für Medizinisch-Biologische Forschung (Novartis Foundation for Medical-Biological Research) FN24-0000000703Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 117.143 IP-LSSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 51NF40_225148Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSK- 3_228959
6 · The paper itself

Abstract

Serotyping identifies bacterial variants based on surface antigens, traditionally using antibody-based assays, but has been increasingly replaced by in silico methods that infer serotypes from genomic sequences for faster, scalable and more reproducible analyses. However, traditional Escherichia coli capsule serotyping has largely fallen out of use since the 1990s, leaving gaps in our knowledge of capsule genetics, diversity, distribution and epidemiology. As capsules influence bacterial interactions with phages, host immune systems and the environment, this gap limits our understanding of E. coli ecology and pathogenicity as well as vaccine and diagnostic development. Here we established a definitive genotype-serotype map for 35 serologically identified and structurally characterized transporter-dependent capsules. We then surveyed 37,723 E. coli genomes, cataloguing 85 transporter-dependent capsule types (K-types), including 55 types that were not part of the reference collection. We leveraged this catalogue to develop a hidden Markov model-based in silico serotyping tool, kTYPr, and applied it to curated sets of 24,015 E. coli genomes and 2,762 metagenome-assembled genomes spanning diverse environmental and clinical sources. We found previously uncharacterized K-types enriched in undersampled environments and associated with E. coli disease. This study expands our understanding of E. coli surface structures, supporting efforts for precision targeting with phage therapy or vaccines.

Indexed as

Bacterial CapsulesEscherichia coliEscherichia coli ProteinsMembrane Transport ProteinsSerotypingComputer SimulationGenetic VariationGenome, BacterialGenotypeHidden Markov ModelsEscherichia coli ProteinsMembrane Transport Proteins

Identifiers

PMID42026126
PMCPMC13171606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.